Enable your GERD- or indigestion patients exclusive access to a digital therapy as part of our studies
We aim to investigate in two parallel pilot studies whether an app can effectively support the conventional therapy of GERD and functional dyspepsia (indigestion).
The objective of the studies is to collect initial data on the hypothesis that Cara Care for heartburn and stomach discomfort can alleviate symptoms more effectively than the respective standard treatment alone.
Study objectives: Evaluation of a digital therapy for gastroesophageal reflux disease (GERD) and functional dyspepsia (indigestion) with Cara Care for heartburn and stomach complaints (CE-marked medical device).
Duration of the intervention: 12 weeks
Design: Non-invasive, not additionally burdensome, multicentric, prospective, two-arm, randomized studies with parallel group design
Number of patients: GERD: 264 • Functional Dyspepsia: 185
Procedure of the studies:
Benefits of Cara Care for heartburn and stomach discomfort
A win-win situation for you and your patients.
Benefits for your patients
- Patients receive a compensation of up to 80 € in vouchers for full participation in the study.
- Control group participants get access to the full app for another 3 months after 12 weeks.
- By participating in one of our studies, patients help others affected
Your benefits
- You support innovative scientific progress.
- No extra effort for you as a recruiting doctor, as patients go through the therapy independently.
- You receive a compensation for included participants.
The functions
of our app
We meet the highest standards for digital therapy.
Linda Weißer
Medical Director
Prof. Dr. med. Joachim Labenz
Facharzt für Innere Medizin und Gastroenterologie/Hepatologie
Senior Consultant für das Centrum Gastroenterologie Bethanien am Bethanien Krankenhaus Frankfurt
Leitlinienautor der aktuellen GERD-Leitlinie